In the last trading session, 2.99 million Humacyte Inc (NASDAQ:HUMA) shares changed hands as the company’s beta touched 1.49. With the company’s per share price at $5.52 changed hands at -$0.26 or -4.50% during last session, the market valuation stood at $759.48M. HUMA’s last price was a discount, traded about -80.62% off its 52-week high of $9.97. The share price had its 52-week low at $2.08, which suggests the last value was 62.32% up since then. When we look at Humacyte Inc’s average trading volume, we note the 10-day average is 3.08 million shares, with the 3-month average coming to 3.00 million.
Analysts gave the Humacyte Inc (HUMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HUMA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Humacyte Inc’s EPS for the current quarter is expected to be -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA was in red as seen at the end of in last trading. With action 8.88%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 94.37%, with the 5-day performance at 8.88% in the green. However, in the 30-day time frame, Humacyte Inc (NASDAQ:HUMA) is -3.66% down. Looking at the short shares, we see there were 16.68 million shares sold at short interest cover period of 6.18 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 8.0% from its current market value. According to analyst projections, HUMA’s forecast low is 5 with 10 as the target high. To hit the forecast high, the stock’s price needs a -81.16% plunge from its current level, while the stock would need to tank 9.42% for it to hit the projected low.
Humacyte Inc (HUMA) estimates and forecasts
Data shows that the Humacyte Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 0.73% over the past 6 months, a -10.28% in annual growth rate that is considerably lower than the industry average of 16.80%.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 350k. 4 analysts are of the opinion that Humacyte Inc’s revenue for the current quarter will be 2.7M.
The 2024 estimates are for Humacyte Inc earnings to decrease by -19.49%.
HUMA Dividends
Humacyte Inc is expected to release its next quarterly earnings report in December.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 27.91% of Humacyte Inc shares while 25.91% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 35.95%. There are 25.91% institutions holding the Humacyte Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 6.5961% of the shares, roughly 7.14 million HUMA shares worth $34.27 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30.
